What is the recommended management for a patient with membranous glomerulopathy?

Management of Membranous Glomerulopathy

For patients with membranous nephropathy (MN) and at least one risk factor for disease progression, use rituximab or cyclophosphamide with alternate-month glucocorticoids for 6 months, or tacrolimus-based therapy for 6 months, with the choice depending on risk stratification. 1

Risk Stratification and Treatment Indications

The decision to initiate immunosuppressive therapy hinges on identifying patients at risk for progression:

Patients Who Require Immunosuppressive Therapy:

• Proteinuria >3.5 g/day with elevated anti-PLA2R antibody levels at diagnosis 2
• Persistent nephrotic-range proteinuria (>3.5 g/day) after 6 months of maximal supportive care 1, 2
• Complications of nephrotic syndrome (thromboembolic events, severe edema, infections) 1
• Declining renal function despite conservative management 3

Patients Who Do NOT Require Immunosuppressive Therapy:

• Non-nephrotic proteinuria (<3.5 g/day) with serum albumin >30 g/L and eGFR >60 ml/min per 1.73 m² - these patients have favorable outcomes without immunosuppression and should receive supportive care only 1
• Absent or low anti-PLA2R antibody levels - associated with higher rates of spontaneous remission 2

Supportive Care (All Patients from Diagnosis)

Blood Pressure and Proteinuria Management:

• Target systolic blood pressure <120 mmHg using standardized office measurement 1
• ACE inhibitor or ARB uptitrated to maximally tolerated dose as first-line therapy for hypertension and proteinuria 1
• Critical caveat: Do NOT start ACEi/ARB in patients with abrupt-onset nephrotic syndrome - these drugs can cause acute kidney injury, especially in minimal change disease 1
• Monitor creatinine closely: tolerate up to 30% stable increase, but stop if kidney function continues worsening or refractory hyperkalemia develops 1

Dietary and Lifestyle Modifications:

• Restrict dietary sodium to <2.0 g/day (<90 mmol/day) 1
• Weight normalization, smoking cessation, regular exercise 1
• Intensify sodium restriction further in patients failing to achieve proteinuria reduction on maximal medical therapy 1

Edema Management:

• Loop diuretics as first-line for volume overload 1
• For diuretic-resistant edema: consider combination therapy with loop diuretics plus thiazides, amiloride (reduces potassium loss), or intravenous albumin with loop diuretics 1

Cardiovascular Risk Reduction:

• Consider statin therapy for persistent hyperlipidemia, particularly in patients with additional cardiovascular risk factors (hypertension, diabetes) 1
• Assess ASCVD risk and align statin intensity accordingly 1

Immunosuppressive Treatment Options

First-Line Regimens (Choose Based on Patient Factors):

Rituximab (Preferred by Most Physicians and Patients):

• High remission rates with better tolerance profile compared to cyclophosphamide 3
• Particularly appropriate for patients concerned about cyclophosphamide toxicity 1

Cyclophosphamide + Alternating Monthly Glucocorticoids (6 months):

• Can induce long-term remission and preserve renal function 1, 3
• Most well-informed patients with very high risk of kidney failure would choose this over conservative treatment 1
• Significant concern: severe short- and long-term side effects with alkylating agents including malignancy risk, infertility, and infections 1
• Meta-analysis shows improved complete remission rates (relative chance 4.8) but no proven renal survival benefit 4

Calcineurin Inhibitors (Tacrolimus or Cyclosporine for 6 months):

• Can induce remission but relapses are frequent after drug withdrawal 3
• Consider for patients who cannot tolerate or refuse cyclophosphamide/rituximab 1

Agents with Limited or Uncertain Efficacy:

Mycophenolate Mofetil:

• Monotherapy appears ineffective 3
• May have benefit when combined with steroids, but evidence is limited 3

Corticosteroids Alone:

• Meta-analysis shows no improvement in renal survival and uncertain benefit for complete remission (relative chance 1.55, not statistically significant) 4
• Should not be used as monotherapy 4

Monitoring and Follow-Up

• Anti-PLA2R antibody levels can predict response: proteinuria may persist for months after antibody becomes undetectable (immunologic remission precedes clinical remission) 2
• Approximately 70-80% of primary MN cases are PLA2R-positive, 3-5% are THSD7A-positive, and the remainder likely have unidentified anti-podocyte antibodies 2
• Monitor for complications of nephrotic syndrome: thromboembolic events (particularly renal vein thrombosis), infections, and cardiovascular disease 5

Prognosis with Appropriate Management

• Untreated natural history: one-third spontaneous remission, one-third progress to ESRD over 10 years, one-third develop non-progressive CKD 2
• With proper management, only 10% or less develop ESRD over 10 years 2
• Patients with moderate renal insufficiency may benefit from treatment but experience more frequent and serious side effects 3

Key Pitfalls to Avoid

• Do not withhold supportive care while waiting to assess disease trajectory - all patients should receive maximal conservative management from diagnosis 1, 2
• Do not start ACEi/ARB in acute-onset nephrotic syndrome without ruling out minimal change disease 1
• Do not use corticosteroids as monotherapy - ineffective for renal survival 4
• Consider repeat kidney biopsy if renal function deteriorates unexpectedly - acute interstitial nephritis can be superimposed on membranous nephropathy, particularly with drug exposures (PPIs, antibiotics, diuretics) 6